Bincy P. Abraham, MD

Fondren Distinguished Professor in Inflammatory Bowel Disease, Department of Medicine
Professor of Clinical Medicine, Academic Institute
Full Clinical Member, Research Institute
Program Director, Gastroenterology Fellowship Program, Lynda K. and David M. Underwood Center for Digestive Disorders
Houston Methodist
Weill Cornell Medical College


Bincy P. Abraham, MD, MS, is professor of clinical medicine in the Academic Division of Gastroenterology and Hepatology at Houston Methodist – Weill Cornell in Houston, Texas.

Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.

Description of Research

Dr. Abraham is a principal investigator and coinvestigator in several key clinical trials. As author or coauthor, Dr. Abraham’s work has been published in peer-reviewed medical journals including Clinical Gastroenterology and Hepatology, American Journal of Gastroenterology, and Inflammatory Bowel Diseases.

Areas Of Expertise

Crohn's disease Pregnancy & inflammatory bowel disease Transition of care in inflammatory bowel disease Ulcerative colitis

The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients
Liu, JJ, Abraham, BP, Adamson, P, Barnes, EL, Brister, KA, Damas, OM, Glover, SC, Hooks, K, Ingram, A, Kaplan, GG, Loftus, EV, McGovern, DPB, Narain-Blackwell, M, Odufalu, FD, Quezada, S, Reeves, V, Shen, B, Stappenbeck, TS & Ward, L 2023, , Inflammatory bowel diseases, vol. 29, no. 2, pp. 297-307.

Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease
Papamichael, K, Vande Casteele, N, Abraham, BP, Ritter, T, Jain, A & Cheifetz, AS 2023, , Clinical Gastroenterology and Hepatology.

Ustekinumab Exposure in Pregnant Women from Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up to 5 Years in Crohn's Disease and 2 Years in Ulcerative Colitis
Abraham, BP, Ott, E, Busse, C, Murphy, C, Miller, L, Baumgart, DC, Scherl, E & Gasink, C 2022, , Crohns and Colitis 360, vol. 4, no. 3, otac025.

Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium
Shen, B, Kochhar, GS, Rubin, DT, Kane, SV, Navaneethan, U, Bernstein, CN, Cross, RK, Sugita, A, Schairer, J, Kiran, RP, Fleshner, P, McCormick, JT, DHoore, A, Shah, SA, Farraye, FA, Kariv, R, Liu, X, Rosh, J, Chang, S, Scherl, E, Schwartz, DA, Kotze, PG, Bruining, DH, Philpott, J, Abraham, B, Segal, J, Sedano, R, Kayal, M, Bentley-Hibbert, S, Tarabar, D, El-Hachem, S, Sehgal, P, Picoraro, JA, Vermeire, S, Sandborn, WJ, Silverberg, MS & Pardi, DS 2022, , The Lancet Gastroenterology and Hepatology, vol. 7, no. 1, pp. 69-95.

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
Abraham, B, Eksteen, B, Nedd, K, Kale, H, Patel, D, Stephens, J, Shelbaya, A, Chambers, R & Soonasra, A 2022, , Advances in Therapy, vol. 39, no. 5, pp. 2109-2127.

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease
Alayo, QA, Fenster, M, Altayar, O, Glassner, KL, Llano, E, Clark-Snustad, K, Patel, A, Kwapisz, L, Yarur, AJ, Cohen, BL, Ciorba, MA, Thomas, D, Lee, SD, Loftus, EV, Fudman, DI, Abraham, BP, Colombel, JF & Deepak, P 2022, , Crohns and Colitis 360, vol. 4, no. 1, otac002.

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
Saleh, A, Ansari, U, Abughazaleh, S, Glassner, K & Abraham, BP 2022, , Biologics: Targets and Therapy, vol. 16, pp. 67-83.

P013 Resolution of Infliximab Associated Infusion Hypersensitivity After Switching to Biosimilar Infliximab-dyyb
Malcolm, I, Rosalind, B, Heather, L & Bincy, A 2021, , The American Journal of Gastroenterology, vol. 116, pp. S3.

Health Maintenance Consensus for Adults with Inflammatory Bowel Disease
Syal, G, Serrano, M, Jain, A, Cohen, BL, Rieder, F, Stone, C, Abraham, B, Hudesman, D, Malter, L, McCabe, R, Holubar, S, Afzali, A, Cheifetz, AS, Gaidos, JKJ & Moss, AC 2021, , Inflammatory bowel diseases, vol. 27, no. 10, pp. 1552-1563.

Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium
Shen, B, Kochhar, GS, Kariv, R, Liu, X, Navaneethan, U, Rubin, DT, Cross, RK, Sugita, A, DHoore, A, Schairer, J, Farraye, FA, Kiran, RP, Fleshner, P, Rosh, J, Shah, SA, Chang, S, Scherl, E, Pardi, DS, Schwartz, DA, Kotze, PG, Bruining, DH, Kane, SV, Philpott, J, Abraham, B, Segal, J, Sedano, R, Kayal, M, Bentley-Hibbert, S, Tarabar, D, El-Hachem, S, Sehgal, P, McCormick, JT, Picoraro, JA, Silverberg, MS, Bernstein, CN, Sandborn, WJ & Vermeire, S 2021, , The Lancet Gastroenterology and Hepatology, vol. 6, no. 10, pp. 826-849.

Vitamin D Receptor Gene Single Nucleotide Polymorphisms and Association with Vitamin D Levels and Endoscopic Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Study
Shirwaikar Thomas, A, Criss, ZK, Shroyer, NF & Abraham, BP 2021, , Inflammatory bowel diseases, vol. 27, no. 8, pp. 1263-1269.

Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis
Abraham, B & Glassner, K 2021, , Current opinion in gastroenterology, vol. 37, no. 4, pp. 344-350.

Risk factors for and frequency of ct scans, steroid use, and repeat visits in inflammatory bowel disease patients seen at a single-center emergency department: A retrospective cohort study
Euers, L, Abughazaleh, S, Glassner, K, Gajula, P, Jones-Pauley, M, Ezeana, C, Puppala, M, Wang, L, Wong, S, Oglat, A, Nickerson, S & Abraham, BP 2021, , Journal of Clinical Medicine, vol. 10, no. 12, 2679.

Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease
Agrawal, T, Acquah, I, Dey, AK, Glassner, K, Abraham, B, Blankstein, R, Virani, SS, Blaha, MJ, Valero-Elizondo, J, Mehta, N, Quigley, EM, Cainzos-Achirica, M & Nasir, K 2021, , American journal of preventive cardiology, vol. 6, pp. 100171.

Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease
Osterman, MT, Vandussen, KL, Gordon, IO, Davis, EM, Li, K, Simpson, K, Ciorba, M, Glover, SC, Abraham, B, Guo, X, Yee, EU, Allard, FD, Perrigoue, JG, Claggett, B, Shen, B, Stappenbeck, TS & Liu, JJ 2021, , Inflammatory bowel diseases, vol. 27, no. 5, pp. 677-685.

Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease
Long, MD, Siegel, CA, Abraham, BP, Chiorean, M & Mahadevan, U 2022, , Clinical Gastroenterology and Hepatology, vol. 20, no. 3, pp. 706-708.e1.

Inflammatory Bowel Disease and Atherosclerotic Cardiovascular Disease: JACC Review Topic of the Week
Cainzos-Achirica, M, Glassner, K, Zawahir, HS, Dey, AK, Agrawal, T, Quigley, EMM, Abraham, BP, Acquah, I, Yahya, T, Mehta, NN & Nasir, K 2020, , Journal of the American College of Cardiology, vol. 76, no. 24, pp. 2895-2905.

Mucosal biomarker of innate immune activation predicts response to vedolizumab in crohn s disease
Osterman, MT, Gordon, IO, Davis, EM, Ciorba, M, Glover, SC, Abraham, B, Khan, F, Guo, X, Yee, EU, Allard, FD, Claggett, B, Shen, B & Liu, JJ 2020, , Inflammatory bowel diseases, vol. 26, no. 10, pp. 1554-1561.

The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort study
Glassner, K, Oglat, A, Duran, A, Koduru, P, Perry, C, Wilhite, A & Abraham, BP 2020, , Journal of Digestive Diseases, vol. 21, no. 5, pp. 264-271.

Erratum: Antibiotics and probiotics in inflammatory bowel disease: When to use them? (Frontline Gastroenterology (2020) 11 (62–69) DOI: 10.1136/flgastro-2018-101057)
Abraham, B & Quigley, EMM 2020, , Frontline Gastroenterology, vol. 11, no. 3, pp. E1.